Published Jun 17, 2026, 7:27 AM ET · Updated 5 months ago · 1 source
UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy
bloomberg
·
Original Report
INFERY
UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.